Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer (DATA)
A Prospective Randomised, Open, Multicentre, Phase III Study to Assess Different Durations of Anastrozole Therapy After 2 to 3 Years Tamoxifen as Adjuvant Therapy in Postmenopausal Women With Breast Cancer.
Sponsor: Maastricht University Medical Center
Listed as NCT00301457, this PHASE3 trial focuses on Breast Cancer and remains completed. Sponsored by Maastricht University Medical Center, it has been updated 13 times since 2006, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Nov 2022 — Mar 2023 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
▶ Show 8 earlier versions
-
Jan 2021 — Nov 2022 [monthly]
Active Not Recruiting PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Oct 2018 — Sep 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Jul 2017 — May 2018 [monthly]
Active Not Recruiting PHASE3
Status: Completed → Active Not Recruiting
-
Feb 2017 — Jul 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jun 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Maastricht University Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .